I 

110TH CONGRESS 

1ST SESSION H. R. 1432 

To prohibit brand name drug companies from compensating generic drug 

companies to delay the entry of a generic drug into the market. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 9, 2007 

Mr. WAXMAN introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on 

the Judiciary, for a period to be subsequently determined by the Speaker, 

in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To prohibit brand name drug companies from compensating 

generic drug companies to delay the entry of a generic 

drug into the market. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Preserve Access to Af5 fordable Generics Act’’. 

6 SEC. 2. CONGRESSIONAL FINDINGS AND DECLARATION OF 

7 PURPOSES. 

8 (a) FINDINGS.—The Congress finds that— 


ycherry on PROD1PC64 with BILLS
2 

•HR 1432 IH

1 (1) prescription drugs make up 11 percent of 

2 the national health care spending but are 1 of the 

3 largest and fastest growing health care expenditures; 

4 (2) 56 percent of all prescriptions dispensed in 

5 the United States are generic drugs, yet they ac6 count for only 13 percent of all expenditures; 

7 (3) generic drugs, on average, cost 63 percent 

8 less than their brand-name counterparts; 

9 (4) consumers and the health care system 

10 would benefit from free and open competition in the 

11 pharmaceutical market and the removal of obstacles 

12 to the introduction of generic drugs; 

13 (5) full and free competition in the pharma14 ceutical industry, and the full enforcement of anti15 trust law to prevent anticompetitive practices in this 

16 industry, will lead to lower prices, greater innova17 tion, and inure to the general benefit of consumers; 

18 (6) the Federal Trade Commission has deter19 mined that some brand name pharmaceutical manu20 facturers collude with generic drug manufacturers to 

21 delay the marketing of competing, low-cost, generic 

22 drugs; 

23 (7) collusion by the brand name pharmaceutical 

24 manufacturers is contrary to free competition, to the 


ycherry on PROD1PC64 with BILLS
3 

•HR 1432 IH

1 interests of consumers, and to the principles under2 lying antitrust law; 

3 (8) in 2005, 2 appellate court decisions reversed 

4 the Federal Trade Commission’s long-standing posi5 tion, and upheld settlements that include pay-offs by 

6 brand name pharmaceutical manufacturers to ge7 neric manufacturers designed to keep generic com8 petition off the market; 

9 (9) in the 6 months following the March 2005 

10 court decisions, the Federal Trade Commission 

11 found there were three settlement agreements in 

12 which the generic received compensation and agreed 

13 to a restriction on its ability to market the product; 

14 (10) the Federal Trade Commission found that 

more than 2 15 ⁄3 of the approximately ten settlement 

16 agreements made in 2006 include a pay-off from the 

17 brand in exchange for a promise by the generic com18 pany to delay entry into the market; and 

19 (11) settlements which include a payment from 

20 a brand name manufacturer to a generic manufac21 turer to delay entry by generic drugs are anti-com22 petitive and contrary to the interests of consumers. 

23 (b) PURPOSES.—The purposes of this Act are— 

24 (1) to enhance competition in the pharma25 ceutical market by prohibiting anticompetitive agreeVerDate Aug 31 2005 18:04 Mar 10, 2007 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1432.IH H1432

ycherry on PROD1PC64 with BILLS
4 

•HR 1432 IH

1 ments and collusion between brand name and ge2 neric drug manufacturers intended to keep generic 

3 drugs off the market; 

4 (2) to support the purpose and intent of anti5 trust law by prohibiting anticompetitive agreements 

6 and collusion in the pharmaceutical industry; and 

7 (3) to clarify the law to prohibit payments from 

8 brand name to generic drug manufacturers with the 

9 purpose to prevent or delay the entry of competition 

10 from generic drugs. 

11 SEC. 3. UNLAWFUL COMPENSATION FOR DELAY. 

12 The Clayton Act (15 U.S.C. 12 et seq.) is amended— 

13 (1) by redesignating section 28 as section 29; 

14 and 

15 (2) by inserting after section 27 the following: 

16 ‘‘SEC. 28. UNLAWFUL INTERFERENCE WITH GENERIC MAR17 KETING. 

18 ‘‘(a) It shall be unlawful under this Act for any per19 son, in connection with the sale of a drug product, to di20 rectly or indirectly be a party to any agreement resolving 

21 or settling a patent infringement claim which— 

22 ‘‘(1) an ANDA filer receives anything of value; 

23 and 


ycherry on PROD1PC64 with BILLS
5 

•HR 1432 IH

1 ‘‘(2) the ANDA filer agrees not to research, de2 velop, manufacture, market, or sell the ANDA prod3 uct for any period of time. 

4 ‘‘(b) Nothing in this section shall prohibit a resolu5 tion or settlement of patent infringement claim in which 

6 the value paid by the NDA holder to the ANDA filer as 

7 a part of the resolution or settlement of the patent in8 fringement claim includes no more than the right to mar9 ket the ANDA product prior to the expiration of the pat10 ent that is the basis for the patent infringement claim. 

11 ‘‘(c) In this section: 

12 ‘‘(1) The term ‘agreement’ means anything that 

13 would constitute an agreement under section 1 of 

14 the Sherman Act (15 U.S.C. 1) or section 5 of the 

15 Federal Trade Commission Act (15 U.S.C. 45). 

16 ‘‘(2) The term ‘agreement resolving or settling 

17 a patent infringement claim’ includes, any agree18 ment that is contingent upon, provides a contingent 

19 condition for, or is otherwise related to the resolu20 tion or settlement of the claim. 

21 ‘‘(3) The term ‘ANDA’ means an abbreviated 

22 new drug application, as defined under section 

23 505(j) of the Federal Food, Drug, and Cosmetic Act 

24 (21 U.S.C. 355(j)). 


ycherry on PROD1PC64 with BILLS
6 

•HR 1432 IH

1 ‘‘(4) The term ‘ANDA filer’ means a party who 

2 has filed an ANDA with the Federal Drug Adminis3 tration. 

4 ‘‘(5) The term ‘ANDA product’ means the 

5 product to be manufactured under the ANDA that 

6 is the subject of the patent infringement claim. 

7 ‘‘(6) The term ‘drug product’ means a finished 

8 dosage form (e.g., tablet, capsule, or solution) that 

9 contains a drug substance, generally, but not nec10 essarily, in association with 1 or more other ingredi11 ents, as defined in section 314.3(b) of title 21, Code 

12 of Federal Regulations. 

13 ‘‘(7) The term ‘NDA’ means a new drug appli14 cation, as defined under section 505(b) of the Fed15 eral Food, Drug, and Cosmetic Act (21 U.S.C. 

16 355(b)). 

17 ‘‘(8) The term ‘NDA holder’ means— 

18 ‘‘(A) the party that received FDA approval 

19 to market a drug product pursuant to an NDA; 

20 ‘‘(B) a party owning or controlling enforce21 ment of the patent listed in the Approved Drug 

22 Products With Therapeutic Equivalence Eval23 uations (commonly known as the ‘FDA Orange 

24 Book’) in connection with the NDA; or 


ycherry on PROD1PC64 with BILLS
7 

•HR 1432 IH

1 ‘‘(C) the predecessors, subsidiaries, divi2 sions, groups, and affiliates controlled by, con3 trolling, or under common control with any of 

4 the entities described in subclauses (i) and (ii) 

5 (such control to be presumed by direct or indi6 rect share ownership of 50 percent or greater), 

7 as well as the licensees, licensors, successors, 

8 and assigns of each of the entities. 

9 ‘‘(9) The term ‘patent infringement’ means in10 fringement of any patent or of any filed patent ap11 plication, extension, reissue, renewal, division, con12 tinuation, continuation in part, reexamination, pat13 ent term restoration, patents of addition and exten14 sions thereof. 

15 ‘‘(10) The term ‘patent infringement claim’ 

16 means any allegation made to an ANDA filer, 

17 whether or not included in a complaint filed with a 

18 court of law, that its ANDA or ANDA product may 

19 infringe any patent held by, or exclusively licensed 

20 to, the NDA holder of the drug product.’’. 

21 SEC. 4. NOTICE AND CERTIFICATION OF AGREEMENTS. 

22 (a) NOTICE OF ALL AGREEMENTS.—Section 

23 1112(c)(2) of the Medicare Prescription Drug, Improve24 ment, and Modernization Act of 2003 (21 U.S.C. 3155 

25 note) is amended by— 


ycherry on PROD1PC64 with BILLS
8 

•HR 1432 IH

1 (1) striking ‘‘the Commission the’’ and insert2 ing ‘‘the Commission (1) the’’; and 

3 (2) inserting before the period at the end the 

4 following: ‘‘; and (2) a description of the subject 

5 matter of any other agreement the parties enter into 

6 within 30 days of an entering into an agreement 

7 covered by subsection (a) or (b)’’. 

8 (b) CERTIFICATION OF AGREEMENTS.—Section 1112 

9 of such Act is amended by adding at the end the following: 

10 ‘‘(d) CERTIFICATION.—The Chief Executive Officer 

11 or the company official responsible for negotiating any 

12 agreement required to be filed under subsection (a), (b), 

13 or (c) shall execute and file with the Assistant Attorney 

14 General and the Commission a certification as follows: ‘I 

15 declare under penalty of perjury that the following is true 

16 and correct: The materials filed with the Federal Trade 

17 Commission and the Department of Justice under section 

18 1112 of subtitle B of title XI of the Medicare Prescription 

19 Drug, Improvement, and Modernization Act of 2003, with 

20 respect to the agreement referenced in this certification: 

21 (1) represent the complete, final, and exclusive agreement 

22 between the parties; (2) include any ancillary agreements 

23 that are contingent upon, provide a contingent condition 

24 for, or are otherwise related to, the referenced agreement; 

25 and (3) include written descriptions of any oral agreeVerDate Aug 31 2005 18:04 Mar 10, 2007 Jkt 059200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\H1432.IH H1432

ycherry on PROD1PC64 with BILLS
9 

•HR 1432 IH

1 ments, representations, commitments, or promises be2 tween the parties that are responsive to subsection (a) or 

3 (b) of such section 1112 and have not been reduced to 

4 writing.’.’’. 

5 SEC. 5. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 

6 Section 505(j)(5)(D)(i)(V) of the Federal Food, Drug 

7 and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) is 

8 amended by inserting ‘‘section 28 of the Clayton Act or’’ 

9 after ‘‘that the agreement has violated’’. 

10 SEC. 6. AUTHORIZATION OF APPROPRIATIONS. 

11 There are authorized to be appropriated to the Fed12 eral Trade Commission such sums as may be necessary 

13 to carry out the provisions of this Act. 

Æ 


ycherry on PROD1PC64 with BILLS